Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $39.69 USD
Change Today -0.93 / -2.29%
Volume 2.3M
GSK On Other Exchanges
Symbol
Exchange
OTC US
New York
Xetra
London
Mexico
Frankfurt
As of 8:04 PM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

Transactions by GLAXOSMITHKLINE PLC-SPON ADR (GSK) in the last 6 months

Announced 08/21/15
1.03B for GlaxoSmithKline plc, Remaining Rights to Ofatumumab
Merger/Acquisition

Novartis Pharma AG entered into an agreement to acquire all remaining rights to Ofatumumab from GlaxoSmithKline plc (LSE:GSK) for $1 billion on August 21, 2015. Under the terms of the agreement, Novartis will make an initial upfront payment of $300 million at closing to GlaxoSmithKline for the acquisition of the compound and a further payment of $200 million payable subject to the start of a phase III study in MS by Novartis. Upon completion of pre-determined milestones, ...
Read More


GSK's price was unchanged after the transaction was announced on 08/21/15.
Investor / Buyer
Novartis Pharma AG
Creditor / Lender
GlaxoSmithKline plc
 
Announced 06/22/15
82.00M for GlaxoSmithKline plc, Nimenrix and Mencevax
Merger/Acquisition

Pfizer Ireland Pharmaceuticals signed an agreement to acquire Nimenrix and Mencevax from GlaxoSmithKline plc (LSE:GSK) for £82 million on June 22, 2015. The total consideration includes some deferred consideration. Nimenrix and Mencevax reported sales of £34 million in 2014. The agreement remains subject to final European Commission approval, other regulatory approvals and other customary closing conditions. The deal is expected to be completed before the end of the ...
Read More


GSK's price was unchanged after the transaction was announced on 06/22/15.
Investor / Buyer
Pfizer Ireland Pharmaceuticals
Creditor / Lender
GlaxoSmithKline plc
 
Announced 06/2/15
226.00M for GlaxoSmithKline plc, Portfolio of Well Established Over the Counter Brands
Merger/Acquisition

Perrigo Company Public Limited Company (NYSE:PRGO) entered into an agreement to acquire portfolio of well established over the counter brands from GlaxoSmithKline plc (LSE:GSK) in cash on June 2, 2015. Portfolio includes well-established European brands in the areas of nicotine replacement therapy, cold and flu, and cold sore management. The portfolio of brands recorded net sales of approximately $110 million in 2014. The deal is subject to approval by the European Commission, ...
Read More


GSK's price was unchanged after the transaction was announced on 06/2/15.
Investor / Buyer
Perrigo Company Public Limited Company
Creditor / Lender
GlaxoSmithKline plc
 
Announced 03/13/15
Valneva SE
Merger/Acquisition

GlaxoSmithKline plc (LSE:GSK) acquired 4.96% stake in Valneva SE (ENXTPA:VLA) from Novartis AG (SWX:NOVN) on March 3, 2015.


GSK's price was unchanged after the transaction was announced on 03/13/15.
Investor / Buyer
GlaxoSmithKline plc
Creditor / Lender
Novartis AG
 
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GSK:US $39.69 USD -0.93

GSK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $59.77 USD -1.81
Bristol-Myers Squibb Co $57.30 USD -1.45
Celgene Corp $117.39 USD -0.26
Eli Lilly & Co $80.32 USD -1.28
Medtronic PLC $68.98 USD -1.00
View Industry Companies
 

Industry Analysis

GSK

Industry Average

Valuation GSK Industry Range
Price/Earnings 6.5x
Price/Sales 2.7x
Price/Book 9.2x
Price/Cash Flow 6.5x
TEV/Sales 2.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GLAXOSMITHKLINE PLC-SPON ADR, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.